Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1803 plus anti-CD38 antibody in relapsed/refractory multiple myeloma
CTR20252876Phase 2Active
- Sponsor
- Zhixiang Jintai
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of velinotamig in multiple myeloma (MM) (2 arms), sponsored by Zhixiang Jintai. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 2 more. Started Aug 2025; status: active.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20252876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252876.